Hiroshi Haeno

Japenese Home

Last updated: Oct. 3, 2014


Refereed paper

  1. Yamamoto KN, Hirota K, Takeda S, Haeno H . (2014)
    Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers. PLoS One, 9(8):e105724
  2. Haeno H, Maruvka YE, Iwasa Y, Michor F. (2013)
    Stochastic tunneling of two mutations in a population of cancer cells. PLoS One, 8(6):e65724.
  3. Iwami S*, Haeno H*, Michor F. (2012) (*co-first authors)
    A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol 8(2):e1002370.
  4. Haeno H*, Gonen M*, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. (2012) (*co-first authors)
    Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148(1-2):362-75.
  5. Hambardzumyan D*, Cheng YK*, Haeno H*, Holland EC, Michor F. (2011) (*co-first authors)
    The Probable Cell of Origin of NF1-and PDGF-Driven Glioblastomas. PLoS One 6(9):e24454.
  6. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL, Aifantis I. (2011)
    A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230-3.
  7. Haeno H, F. Michor (2009)
    The evolution of tumor metastases during clonal expansion. J Theor Biol 263, 30-44.
  8. Haeno H, R. L. Levine, D. G. Gilliland, F. Michor (2009)
    A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci USA 106, 16616-16621.
  9. Haeno H, Y. Iwasa, F. Michor (2007)
    The evolution of two mutations during clonal expansion. Genetics 177, 2209-2221.
  10. Haeno H, Y. Iwasa (2007)
    Probability of resistance evolution for exponentially growing virus in the host. J Theor Biol 246, 323-331.